Protamine zinc insulin injection

This product is a long-acting animal insulin preparation. After subcutaneous injection, free insulin is gradually released at the injection site and absorbed. The pharmacological action of this product is the same as that of insulin, and its main pharmacodynamic effect is to lower blood sugar. Insulin plays a multi-faceted role in the metabolism and storage of sugar, protein, and fat: 1. It promotes the active transport of glucose by muscles, adipose tissues, etc., promotes glucose catabolism, generates energy, or stores it in the form of glycogen or diglycerides; 2. It promotes the liver to take up glucose and convert it into glycogen; 3. It inhibits the decomposition of liver glycogen and gluconeogenesis, and inhibits the output of liver glucose; 4. It promotes the uptake of sugar, protein, and fat by many tissues, while promoting protein synthesis and inhibiting the release of free fatty acids in fat cells, inhibiting the production of ketone bodies, and regulating material metabolism. For diabetic patients with defective or insufficient insulin secretion, injection of exogenous insulin can correct various metabolic disorders to a certain extent, mainly lowering blood sugar, and can delay or prevent the occurrence of chronic complications of diabetes.

Main ingredients: This product is a sterile suspension of insulin (porcine or bovine) containing protamine and zinc chloride.

It is mainly used for diabetes, especially insulin-dependent diabetes: 1. Severe, emaciated, malnourished patients; 2. Mild and moderate patients who have not responded to diet and oral hypoglycemic drugs; 3. Patients with severe metabolic disorders (such as ketoacidosis, hyperosmotic coma or lactic acidosis), severe infections, wasting diseases (such as tuberculosis, cirrhosis), progressive retinal, renal, and neurological diseases, as well as acute myocardial infarction and cerebrovascular accidents; 4. Patients with pregnancy, delivery, and major surgery. It can also be used to correct intracellular potassium deficiency.

This product is injected subcutaneously 30 to 60 minutes before breakfast. Initial treatment is once a day, 4 to 8 units each time, and the maintenance dose is adjusted according to changes in blood sugar and urine sugar. Sometimes it is necessary to inject again before dinner. The dose depends on the condition, and the total daily amount is generally 10 to 20 units. Before use, the medicine bottle must be rolled to mix the insulin, but do not shake it vigorously to avoid bubbles. Used in combination with regular insulin: At the beginning, the dosage ratio of regular insulin and this product is 2 to 3:1, and the dosage is adjusted according to the condition. When this product is mixed with regular insulin, part of the regular insulin will be converted into long-acting insulin. When using it, the regular insulin should be drawn first, and then this product. Dose adjustment: The amount of insulin should be adjusted with the patient's exercise or dietary changes.

1. Hypoglycemia reaction: It is caused by improper use of insulin. Hypoglycemia reaction is easy to occur when insulin is overdosed, meals are not taken in time after insulin injection, or more intense physical activities are performed (increased muscle glucose uptake). The early symptoms of hypoglycemia reaction are weakness, hunger, dizziness, cold sweat, pale skin, palpitations, excitement, hand tremors, nervousness, headache, tremors and other symptoms similar to sympathetic nerve excitement; further development into depression, inattention, drowsiness, lack of judgment and self-control, forgetfulness, hemiplegia, ataxia, tachycardia, diplopia, paresthesia, and convulsions and coma in severe cases. 2. Allergic reaction: Allergic reaction can be systemic and local allergy. Local allergy is manifested as erythema, papules, and nodules at the injection site, which generally occurs a few hours or days after insulin injection. Systemic allergic reaction occurs immediately after insulin injection, with urticaria all over the body, which may be accompanied or not accompanied by angioneurotic edema, respiratory symptoms (such as asthma, dyspnea), and extremely rare hypotension, shock, and even death. Therefore, when injecting this product for the first time, you should pay close attention to the patient's sensitivity to this product to prevent allergic reactions. 3. Fat atrophy at the injection site: more common in young women, mostly caused by fat dissolution reaction caused by impure insulin preparations. 4. Fat hyperplasia at the injection site: a fat-producing reaction caused by insulin. Injecting in different sites in turn can reduce this reaction.

Hypoglycemia, pancreatic islet cell tumor.

1. Glucocorticoids, adrenocortical hormones target = _blank adrenocorticotropic hormone, glucagon, estrogen, oral contraceptives, thyroxine, adrenaline, thiazide diuretics, diazoxide, beta;2-receptor agonists, H2-receptor blockers, calcium channel blockers, clonidine, phenytoin sodium, etc. can increase blood sugar concentration. When used together, the dose of these drugs or insulin should be adjusted. 2. Oral hypoglycemic drugs and insulin have a synergistic hypoglycemic effect. 3. Anticoagulants, salicylates, sulfonamides and anti-tumor drugs such as methotrexate can compete with insulin and bind to plasma proteins, thereby increasing the level of free insulin in the blood. Non-steroidal anti-inflammatory analgesics can enhance the hypoglycemic effect of insulin. 4. Beta; receptor blockers such as propranolol can prevent the reaction of adrenaline to increase blood sugar, interfere with the body's blood sugar regulation function, and can increase the risk of hypoglycemia when used together with insulin, and can mask certain hypoglycemic symptoms and prolong hypoglycemia. When used together, the dose of insulin should be adjusted. 5 Chloroquine, quinidine, quinine, etc. can delay the degradation of insulin, increase the insulin concentration in the blood, and thus enhance its hypoglycemic effect. 6 Angiotensin-converting enzyme inhibitors, bromocriptine, clofibrate, ketoconazole, lithium, mebendazole, pyridoxine, theophylline, etc. can directly or indirectly affect the lowering of blood sugar in different ways. When insulin is used in combination with the above drugs, the dosage should be appropriately reduced. 7 Octreotide can inhibit the secretion of growth hormone, glucagon and insulin, and delay gastric emptying and slow gastrointestinal motility, causing delayed food absorption, thereby reducing postprandial hyperglycemia. When starting to use octreotide, the insulin dosage should be appropriately reduced and then adjusted according to blood sugar.

Keep tightly closed in a cool place, avoid freezing.

10ml:400 units

Jiuquan Dadeli Pharmaceutical Co., Ltd.

• Founded in:

  2003-04-21

• Address:

  No. 6, Dadeli Road, High-tech Industrial Park, Suzhou District, Jiuquan City, Gansu Province

• Tax NO.:

  9162090074589132XP

• Registered Funds:

  59.43 million yuan

• Website:

  Log in to view

• Email:

  Log in to view